Oracle announced a partnership with the Africa Clinical Research Network (ACRN) to launch the PROTECT‑Africa clinical trial, a study that began in February 2026 and will enroll 1,106 pregnant women across Zimbabwe, Rwanda, and Tanzania. The trial’s goal is to evaluate placental biomarkers that could predict severe pre‑eclampsia, a leading cause of maternal and fetal morbidity in sub‑Saharan Africa.
Oracle’s cloud‑based clinical trial and safety applications—Oracle Clinical One, Argus Safety, and advanced analytics—will automate workflows, manage critical data, and enhance safety reporting throughout the study. By integrating these tools, Oracle aims to streamline trial operations and improve data integrity in a region where clinical research infrastructure is limited.
The partnership marks a significant expansion of Oracle’s life‑sciences footprint into Africa, a market that hosts only about 2 % of global clinical trials. ACRN’s network of 59 sites across 14 countries provides a robust platform for scaling research, while Oracle’s recent Q4 FY2025 results—$15.9 billion in revenue, $6.7 billion in cloud revenue, and a 41 % increase in remaining performance obligations—demonstrate the company’s financial strength and its capacity to invest in emerging markets.
Seema Verma, Oracle’s Executive Vice President and General Manager of Health and Life Sciences, said, "Our collaboration with the Africa Clinical Research Network is a significant step toward advancing modern, patient‑centric research that can help accelerate scientific breakthroughs across Africa." She added, "Together, we are creating the digital framework to enable innovation and AI integration into clinical research across the continent. The organization’s on‑the‑ground expertise and dedication, combined with our cloud‑based clinical trial and safety solutions, create a meaningful opportunity to drive innovation throughout the region, help bridge the research gap between Africa and the rest of the world, and ultimately support better health outcomes for communities."
Tariro Makadzange, CEO of ACRN, noted, "Our mission at ACRN is to empower African researchers to lead and participate in clinical trials that directly address the health needs of our communities." He added, "Oracle's robust and integrated clinical trial and safety solutions will enable us to conduct studies with greater efficiency, transparency, and, most importantly, an unwavering focus on patient well‑being."
The PROTECT‑Africa initiative positions Oracle to capture a large, underserved market, enhance its life‑sciences portfolio, and contribute to global health equity by addressing pre‑eclampsia—a condition that affects approximately 5.3 % of pregnant women in the region. By embedding its integrated data platform into this new vertical, Oracle signals a strategic push toward revenue growth in emerging markets and a commitment to advancing patient‑centric research worldwide.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.